National genomic monitoring programme confirmed
1 June 2021 – Monitoring of the variants of SARS-CoV-2 and the prevalence of the infection in the population are two important elements of efforts to combat the novel coronavirus. Monitoring enables the evolution of the different variants to be tracked and the risk of strains which circumvent the immunity conferred by the different vaccines or prior infection to be evaluated. Against this background, the Federal Office of Public Health (FOPH) has endorsed the establishment of a national genomic monitoring programme for SARS-CoV-2 in collaboration with the Centre for Emerging Viral Diseases at Geneva University Hospitals and the reference laboratory (CRIVE), the Federal Institutes of Technology, university and privately run laboratories, the NextStrain platform and the Covid-19 Scientific Task Force.
For more information, see here.